RAJAF — Cordyceps Sunshine Biotech Holdings Co Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMid Cap
- $577.82m
- $582.14m
- $1.25m
Annual income statement for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.135 | 0 | 0.053 | 0.883 | 1.25 |
| Cost of Revenue | |||||
| Gross Profit | 0.094 | 0 | 0.04 | 0.766 | 0.534 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 0.126 | 0.119 | 0.468 | 0.655 | 1.44 |
| Operating Profit | 0.009 | -0.119 | -0.415 | 0.228 | -0.184 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.012 | -0.119 | -0.415 | 0.191 | -0.191 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.013 | -0.119 | -0.415 | 0.169 | -0.226 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.013 | -0.491 | -0.72 | 0.752 | -0.226 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.013 | -0.491 | -0.72 | 0.752 | -0.226 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0 | -0.001 | -0.004 | 0.002 | -0.002 |